Implications for Behavioral and Social Research of Preclinical Markers of Alzheimer's Disease and Related Dementias

On June 28 and 29, 2021, the National Academies of Sciences, Engineering, and Medicine convened a workshop that addressed behavioral and social science research questions raised by the use of biomarkers and other measures (e.g., digital/sensor data) for pre-clinical AD/ADRD diagnosis, including the personal, social, ethical, legal, economic, health equity, and healthcare implications for patients and families, the impact of disclosure of preclinical diagnosis on identity and self-concept, study partners and interpersonal relationships, interactions with the healthcare system, participation in the workforce, and other outcomes. It also addressed the implications of preclinical diagnosis of AD/ADRD for the design and conduct of AD/ADRD prevention research. The

(PDF, 153K) is available.